Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 8/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633361 | 0.84 | PIK3C3 (0.48) | JAK2JAK1TYK2PIK3C3 | |
| SCHEMBL30633355 | 0.84 | ATR (0.46) | JAK2JAK1TYK2PIK3C3AAK1 | |
| SCHEMBL3323673 | 0.84 | ATR (0.46) | JAK2JAK1TYK2PIK3C3AAK1 | |
| SCHEMBL12975420 | 0.82 | L3MBTL1 (0.55) | JAK2JAK1TYK2PIK3C3 | |
| SCHEMBL26686195 | 0.81 | EGFR (0.46) | TP53 | |
| SCHEMBL10276435 | 0.81 | TP53 (0.60) | JAK2JAK1TYK2TP53 | |
| SCHEMBL25600283 | 0.81 | JAK2 (0.52) | JAK2JAK1TYK2PIK3C3AAK1 | |
| SCHEMBL12987908 | 0.80 | ACVRL1 (0.43) | PIK3C3TP53 | |
| SCHEMBL23212152 | 0.79 | TYK2 (0.57) | TYK2TP53 | |
| SCHEMBL16923772 | 0.79 | JAK2 (0.51) | JAK2JAK1TYK2PIK3C3AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20200237737-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-07-30 | — | — | US | disclosed |
| US-10660881-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190314348-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-10-17 | — | — | US | disclosed |
| US-10383863-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| US-10188638-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20170239227-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-08-24 | — | — | US | disclosed |
| US-9688689-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| EP-2549875-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | JAK2 207/4885JAK1 95/4885TYK2 757/4885 |
| US-10188638-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | JAK2 679/4885JAK1 726/4885TYK2 4469/4885 |
| US-20190314348-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | JAK2 679/4885JAK1 726/4885TYK2 4469/4885 |
| US-20200237737-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | JAK2 679/4885JAK1 726/4885TYK2 4469/4885 |
| US-20170239227-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | JAK2 679/4885JAK1 726/4885TYK2 4469/4885 |
| US-10383863-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | JAK2 679/4885JAK1 726/4885TYK2 4469/4885 |
| US-10660881-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | JAK2 679/4885JAK1 726/4885TYK2 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.